A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Healthcare

Major players across the healthcare industry—pharmaceutical and biotechnology companies, medical device and equipment manufacturers, health insurance companies, hospitals and other providers—turn to Simpson Thacher for deep experience navigating the complexities of the industry. From structuring multibillion dollar mergers and obtaining antitrust approval to advising on disputes and investigations, our healthcare group combines industry-specific experience with unrivaled excellence in the legal disciplines that most affect healthcare companies.  
#2
Ranked #2 in 2017 in healthcare M&A in the U.S. (based on the target industry)
(Refinitiv)
290
Over 290 corporate representations with an aggregate value of more than $630 billion in healthcare since 2010
(Refinitiv)
“Simpson Thacher couples ‘an impressive level of experience, industry knowledge and business acumen’ with a ‘deep bench.’”
--The Legal 500 2016
Pharma and Biotech
  • Celltrion Healthcare’s $900 million IPO
  • Blackstones announced acquisition of the entire equity stake in AYUMI Pharmaceutical
  • Valeant in high-profile securities fraud and RICO class actions
  • Blackstones acquisition of Clarus, a life sciences investment firm, marking the launch of Blackstone Life Sciences
  • Celgene’s $74 billion merger with Bristol-Myers Squibb (representing the financial advisors to Celgene)
  • Daiichi Sankyo’s high-profile multidistrict “pay-for-delay” antitrust litigation related to Lipitor
  • Par Pharmaceutical’s $1.5 billion debt offering
  • Walgreens Boots Alliance’s acquisition of 1,932 Rite Aid stores for $4.157 billion
  • Defense of Pfizer in multiple securities litigations
  • The CFO of a pharmaceutical company in a DOJ investigation of suspected violations of the FCPA
  • Bayer and Pfizer in false advertising matters
  • Merck in a high-profile litigation and patent office dispute involving its immunotherapy products, including “the President's Drug” KEYTRUDA, against Genentech over the “Cabilly” patents
Show more
Website_HButtons_160x160_2016_v05_5
  • Avantor's $4.37 billion IPO, the largest healthcare IPO in U.S. history
  • K2M Group Holdings, Inc.’s acquisition by Stryker Corporation for approximately $1.4 billion
  • medical device company in connection with allegations raised relating to FDA and FCPA compliance issues
  • Teleflex’s multiple acquisitions and debt offerings
  • Debt offerings for Boston Scientific
  • EQT’s acquisition of Clinical Innovations
  • Equity offering for Integra LifeSciences
  • Japan’s Panasonic Healthcare’s carve-out acquisition of Bayer AG’s Diabetes Care business division for $1.15 billion
  • Financing for Thermo Fisher in its acquisition of Patheon
  • Acelity’s sale of its LifeCell business unit to Allergan
  • Apax Partners’ joint venture with Becton Dickinson for Respiratory Solutions Business
  • Warburg Pincus in a $76.5 million series C equity funding for Outset Medical
Show more
Payors and Providers
  • CVS Health’s $40 billion debt offering, the third-largest corporate bond sale on record, to finance its announced acquisition of Aetna
  • Cigna’s $1.6 billion debt offering and related tender offers
  • Hellman & Friedman's acquisition of MultiPlan
  • HCA’s IPO (the largest U.S. IPO of 2011) and multiple debt and equity offerings
  • American Renal Holdings’ IPO
  • An insurance carrier concerning a computer data access incident that resulted in investigations by various state and federal government and regulatory entities, including the Department of Health and Human Services and the DOJ
  • Debt offerings of Community Health Systems 
  • Adeptus Health’s, a Sterling Partners portfolio company, IPO and multiple equity follow-on offerings
  • A provider of medical diagnostic services in Brazil Centro de Imagem Diagnósticos S.A. – Alliar’s IPO
  • Debt offerings of UnitedHealth Group 
Show more
Healthcare Services and IT
  • PHC Holdings’ announced $1.14 billion acquisition of the Anatomical Pathology business of Thermo Fisher Scientific 
  • Weight Watchers in securing a dismissal for a securities class action alleging false and misleading statements regarding its financial performance
  • Internet Brands’, a KKR portfolio company, $2.8 billion acquisition of WebMD
  • KKR’s $1.4 billion acquisition of PharMerica, a provider of pharmacy services
  • iKang’s $1.5 billion going private transaction (representing the special committee of the board)
  • Patient experience company Press Ganey’s IPO and multiple acquisitions as well as EQT Partners in its acquisition of the company
  • Contract research organization Quintiles’ merger with IMS Health (representing the independent directors) and Quintiles’ IPO (as special IPO counsel)
  • Blackstone’s $1.5 billion sale of life science and medical real estate assets of Wexford Science & Technology and $1.125 billion acquisition of a portfolio of senior living properties of HCP, Inc.
Show more

HC_Infograph_v07_01

HC_Infograph_v07_02
HC_Infograph_v07_03  HC_Infograph_v07_04
 HC_Infograph_v07_05 HC_Infograph_v07_06
 HC_Infograph_v09_07
 HC_Infograph_v07_08  HC_Infograph_v07_09  HC_Infograph_v07_10

News & Events

    Publications

      Spotlight on
      Simpson Thacher Enhances Healthcare Practice With Addition of Regulatory Counsel Vanessa K. Burrows
      Spotlight on
      Simpson Thacher Hosts 2019 Healthcare Perspectives Event
      Spotlight on
      Juan Naveira Speaks at IBA’s 7th Annual World Life Sciences Conference